Type and hit ENTER

ProAxsis specialises in four key areas of business:

Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
Clinical research services
Academic and Pharmaceutical Company Researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
ProAxsis R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.


  ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces that it has successfully registered a CE Mark for its novel ProteaseTag® Active Proteinase 3 Immunoassay. Furthermore, the company confirms an immediate first commercial sale …

August 2, 2018

ProAxsis will be presenting three abstracts at the COPD 11 Conference, which takes place between June 20th-21st 2018 in Birmingham, UK.  These include: • The Development of a Novel Immunoassay for the Detection and Quantification of Murine Neutrophil Elastase (Ashleigh Kennedy) • Sputum Storage Conditions and their …

June 18, 2018

ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for small businesses in Northern Ireland. The glittering awards ceremony took place on the evening of Thursday May 31st at the Crowne Plaza Hotel in Belfast, and …

June 4, 2018
ProAxsis | developing products for the capture, detection and measurement of active protease biomarkers of disease